Hemodynamic evaluation of the addition of isosorbide-5-mononitrate to nadolol in cirrhotic patients with insufficient response to the β-blocker alone

Hepatology

Volumn 26, Issue 1, 1997, Pages 34-39

  Merkel, Carlo ^a   Sacerdoti, David ^a   Bolognesi, Massimo ^a   Enzo, Edda ^a   Marin, Renato ^b   Bombonato, Giancarlo ^a   Angeli, Paolo ^a   Gatta, Angelo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b General Hospital of Dolo   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ISOSORBIDE 5 NITRATE; NADOLOL;

ADULT; ARTERY BLOOD FLOW; ARTICLE; CLINICAL ARTICLE; DOPPLER FLOWMETRY; DOSE RESPONSE; FEMALE; HEMODYNAMIC MONITORING; HUMAN; LIVER CIRRHOSIS; MALE; PORTAL HYPERTENSION; PORTAL VEIN BLOOD FLOW; PRESSURE GRADIENT; PRIORITY JOURNAL; PULSATILE FLOW;

EID: 0030995729     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510260105     Document Type: Article

References (29)

1. Groszmann RJ, Bosch J, Grace ND, Conn HO, Garcia-Tsao G, Navasa M, Albert J, et al. Hemodynamic events in a prospective randomized trial of propranolol vs. placebo in the prevention of a first variceal hemorrhage. Gastroenterology 1990;99:1401-1407.
2. Sacerdoti D, Merkel C, Gatta A. Importance of the 1-month-effect of nadolol on portal pressure in predicting failure of prevention of rebleeding in cirrhosis. J Hepatol 1991;12:124-125.
3. Feu F, Garcia-Pagan JC, Bosch J, Luca A, Terés J, Escorsell A, Rodés J. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 1995;346:1056-1059.
4. Conn HO. Sclerotherapy versus beta-blockade: unanticipated anomalies of experimental design [Editorial]. Gastroenterology 1993;105:1575-1577.
5. Bosch J, Garcìa-Pagàn JC, Feu F, Luca A, Fernandez M, Pizcueta P, Rodés J. New approaches in the pharmacological treatment of portal hypertension. J Hepatol 1993;17(suppl 2):S41-S45.
6. Garcìa-Pagàn JC, Feu F, Bosch J, Rodés J. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. A randomized controlled study. Ann Intern Med 1991;114: 869-873.
7. Vorobioff J, Picabea E, Gamen M, Villavicencio R, Bordato J, Bessone F, Tanno H, et al. Propranolol compared with propranolol plus isosorbide dinitrate in portal hypertensive patients: long-term hemodynamic and renal effects. HEPATOLOGY 1993;18:477-484.
8. Polio J, Sieber CC, Lerner E, Groszmann RJ. Cardiovascular hyporesponsiveness to nor-epinephrine, propranolol and nitroglycerin in portal hypertensive and aged rats. HEPATOLOGY 1993;18:128-136.
9. Kroeger RJ, Groszmann RJ. Increased portal venous resistance hinders portal pressure reduction during the administration of beta-adrenergic blocking agents in a portal hypertensive model. HEPATOLOGY 1985;5: 97-101.
10. Sabbà C, Merkel C, Zoli M, Ferraioli G, Gaiani S, Sacerdoti D, Bolondi L. Interobserver and interequipment variability of echo-Doppler examination of the portal vein: effect of a co-operative training program. HEPATOLOGY 1995;21:428-433.
11. Moriyasu F, Ban N, Nishida O, Nakamura T, Miyake T, Uchino H, Kanematsu Y. Clinical application of a ultrasonic duplex system in the quantitative measurement of portal blood flow. J Clin Ultrasound 1986; 14:579-588.
12. Bolognesi M, Sacerdoti D, Merkel C, Bombonato G, Enzo E, Gatta A. Effects of chronic therapy with nadolol on portal hemodynamics and on splanchnic impedence indices using Doppler sonography: comparison between acute and chronic effects. J Hepatol 1997;26:305-311.
13. Sacerdoti D, Merkel C, Bolonesi M, Amodio P, Angeli P, Gatta A. Hepatic arterial resistance in cirrhosis with and without portal vein thrombosis: relationships with portal hemodynamics. Gastroenterology 1995;108: 1152-1158.
14. Merkel C, Bolognesi M, Bellon S, Zuin R, Noventa F, Finucci G, Sacerdoti D, et al. Prognostic usefulness of hepatic vein catheterization in patients with cirrhosis and esophageal varices. Gastroenterology 1992; 102:973-979.
15. Lebrec D. Methods to evaluate portal hypertension. Gastroenterol Clin North Am 1992;21:41-59.
16. Lin HC, Tsai YT, Lee FY, Chang TT, Wang SS, Lay CS, Lee SD, et al. Comparison between portal vein pressure and wedged hepatic vein pressure in hepatitis B-related cirrhosis. J Hepatol 1989;9:326-330.
17. Merkel C, Gatta A, Donada C, Enzo E, Marin R, Amodio P, Torboli P, et al. Long-term effect of nadolol or nadolol plus isosorbide-5-mononitrate on renal function and ascites formation in patients with cirrhosis. HEPATOLOGY 1995;22:808-813.
18. Merkel C, Marin R, Enzo E, Donada C, Cavallarin G, Torboli P, Amodio P, et al. Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Lancet 1996;348:1677-1681.
19. Feu F, McCormick PA, Planas R, Burroughs AK, Bosch J, and the Variceal Rebleeding Study Group. Randomized controlled trial comparing propranolol + isosorbide-5-mononitrate vs. shunt surgery/sclerotherapy in the prevention of variceal rebleeding [Abstract]. J Hepatol 1995; 23(suppl 1):69.
20. Villanueva C, Balanzò J, Novella MT, Soriano G, Sàinz S, Torras X, Guarner C, et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J Med 1996;334:1624-1629.
21. DeVries PJ, Van Hattum J, Hoekstra JBL, De Hooge P. Duplex Doppler measurements of portal venous flow in normal subjects: inter- and intraobserver variability. J Hepatol 1991;13:358-363.
22. Watanabe Y, Puschel P, Gardemann A, Jungermann K. Presinusoidal and proximal intrasinusoidal confluence of hepatic artery and portal vein in rat liver: functional evidence by orthograde and retrograde bivascular perfusion. HEPATOLOGY 1994;19:1198-1207.
23. Garcìa-Pagàn JC, Navasa M, Bosch J, Bru C, Pizcueta P, Rodés J. Enhancement of portal pressure reduction by the association of isosorbide-5-mononitrate to propranolol administration in patients with cirrhosis. HEPATOLOGY 1990;11:230-238.
24. Benoit JN, Granger N. Splanchnic hemodynamics in chronic portal hypertension. Semin Liver Dis 1986;6:287-298.
25. Feu F, Bordas JM, Luca A, Garcìa-Pagàn JC, Escorsell A, Bosch J, Rodés J. Reduction of variceal pressure by propranolol: comparison of the effect on portal pressure and azygos blood flow in patients with cirrhosis. HEPATOLOGY 1993;18:1082-1089.
26. Hallemans R, Naeije R, Mois P, Melot C, Reding P. Treatment of portal hypertension with isosorbide dinitrate alone and in combination with vasopressin. Crit Care Med 1983;11:536-540.
27. Merkel C, Finucci G, Zuin R, Bazzerla G, Bolognesi M, Sacerdoti D, Gatta A. Effects of isosorbide dinitrate on portal hypertension in alcoholic cirrhosis. J Hepatol 1987;4:174-180.
28. Bhatal PS, Grossman HJ. Reduction of increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators. J Hepatol 1985;1:325-327.
29. Blei AT, Gottstein J. Isosorbide dinitrate in experimental portal hypertension: a study of factors that modulate the hemodynamic response. HEPATOLOGY 1986;6:107-111.